Arno Therapeutics Inc., of Flemington, N.J., reported data showing AR-12's antifungal activity against onychomycosis, a common fungal infection of the fingernails and toenails, at the American Association of Pharmaceutical Scientists meeting in Orlando, Fla. Read More
Alexion Pharmaceuticals Inc., of Cheshire, Conn., reported third quarter revenues of $666.6 million, a 20 percent jump over the same period in 2014. Read More
The FDA wants to know more about individual and industry experiences in using technologies and innovative methods to more efficiently conduct clinical research. It also is seeking stakeholder perspectives on possible barriers to implementing those technologies and methods. Read More
Mabspace Biosciences Co. Ltd., of Suzhou, China, said it completed a $15 million series A round to advance its pipeline of therapeutic antibody programs into clinical studies, and to enable expanded discovery of antibodies aimed at various components of tumor microenvironment to enhance responses of tumors that may be less likely to respond to T-cell checkpoint monotherapy. Read More
Driven by pricing pressures, biosimilars and the advent of personalized medicines, biologics manufacturing is set to go the way of computers – from massive facilities to a suitcase-sized unit that could produce an individualized drug in the doctor's office. Read More
Several recent studies have given new insights into the molecular underpinnings of post-traumatic stress disorder (PTSD) and its relationship to depression. Read More
Funded and ready to put its "gem cutters" to work, Frazier's managing general partner, Patrick Heron, told BioWorld Today the company has closed its eighth fund, a $262 million tool for finding "diamonds in the rough" of early stage therapeutics companies. Read More
The up front is only $10 million, but Arcturus Therapeutics Inc. stands to collect up to $1.56 billion more from Ultragenyx Pharmaceutical Inc. in a rare disease research collaboration and license deal to discover and develop messenger RNA (mRNA) therapeutics using its unlocked nucleomonomer agent (UNA) oligomer chemistry and Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR) nanoparticle delivery platform. Read More
Prometic Life Sciences Inc., of Laval, Quebec, said the clinical trial application (CTA) for its antifibrotic lead drug candidate, PBI-4050, in patients suffering from a condition associated with type 2 diabetes and severe multi-organ fibrosis has been cleared by the Medicines and Healthcare Products Regulatory Agency in the U.K. Read More
